Paul Tudor Jones Phathom Pharmaceuticals, Inc. Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 34,049 shares of PHAT stock, worth $224,723. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,049
Previous 36,383
6.42%
Holding current value
$224,723
Previous $657,000
57.99%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PHAT
# of Institutions
157Shares Held
68.4MCall Options Held
52.3KPut Options Held
635K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$66.7 Million4.92% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$49.3 Million13.31% of portfolio
-
Jennison Associates LLC7.06MShares$46.6 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA3.67MShares$24.2 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$23.1 Million28.4% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $259M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...